Daratumumab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Daratumumab
Health Canada Patents

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

evonik-m-2025-09-08

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Daratumumab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

4 API Suppliers, 1 USDMF, 3 Listed Suppliers

4 API Suppliers
1 USDMF
3 Listed Suppliers

DEVELOPMENTS

235 Drugs in Development

235 Drugs in Development

FINISHED DOSAGE FORMULATIONS

36 FDF Dossiers, 3 FDA Orange Book, 5 Europe, 3 Canada, 22 Australia, 3 South Africa

36 FDF Dossiers
3 FDA Orange Book
5 Europe
3 Canada
22 Australia
3 South Africa

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 184 News #PharmaBuzz

1 Data Compilation #PharmaFlow
184 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 5 Regulatory FDF Prices, 9 Annual Reports

2 US Medicaid Prescriptions
5 Regulatory FDF Prices
9 Annual Reports

MARKET PLACE

4 FDF Dossiers

4 FDF Dossiers

PATENTS & EXCLUSIVITIES

7 Health Canada Patents

7 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

7 All

01 7Belmore Neidrauer LLP

filter Patent Reset all filters

7 All

01 32602375

02 32664740

03 13004152

filter Product Reset all filters

7 All

01 7DARATUMUMAB

filter Dosage Reset all filters

7 All

01 7SOLUTION

filter Exp Date Reset all filters

7 All

01 32026-03-23

02 32027-09-26

03 12036-11-01

Product Main Page

01

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-23

Date Granted : 2018-07-24

DARATUMUMAB

Brand Name : DARZALEX

Patent Number : 2602375

Filing Date : 2006-03-23

Strength per Unit : 400 mg / 20mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2026-03-23

Date Granted : 2018-07-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-23

Date Granted : 2018-07-24

DARATUMUMAB

Brand Name : DARZALEX

Patent Number : 2602375

Filing Date : 2006-03-23

Strength per Unit : 100 mg / 5 mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2026-03-23

Date Granted : 2018-07-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-23

Date Granted : 2018-07-24

DARATUMUMAB

Brand Name : DARZALEX SC

Patent Number : 2602375

Filing Date : 2006-03-23

Strength per Unit : 1800 mg / 15mL (120mg / mL)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2026-03-23

Date Granted : 2018-07-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-09-26

Date Granted : 2021-11-16

DARATUMUMAB

Brand Name : DARZALEX

Patent Number : 2664740

Filing Date : 2007-09-26

Strength per Unit : 400 mg / 20mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2027-09-26

Date Granted : 2021-11-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-09-26

Date Granted : 2021-11-16

DARATUMUMAB

Brand Name : DARZALEX

Patent Number : 2664740

Filing Date : 2007-09-26

Strength per Unit : 100 mg / 5 mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2027-09-26

Date Granted : 2021-11-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-09-26

Date Granted : 2021-11-16

DARATUMUMAB

Brand Name : DARZALEX SC

Patent Number : 2664740

Filing Date : 2007-09-26

Strength per Unit : 1800 mg / 15mL (120mg / mL)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2027-09-26

Date Granted : 2021-11-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Belmore Neidrauer LLP

DARATUMUMAB

ChemOutsourcing

Not Confirmed

Belmore Neidrauer LLP

Country

ChemOutsourcing

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2036-11-01

Date Granted : 2024-04-16

DARATUMUMAB

Brand Name : DARZALEX SC

Patent Number : 3004152

Filing Date : 2016-11-01

Strength per Unit : 1800 mg / 15mL (120mg / mL)

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2036-11-01

Date Granted : 2024-04-16

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!